Why the fall of a pharmaceutical giant might be really encouraging

Before there was Martin Shkreli, there was Valeant Pharmaceuticals

Valeant Pharmaceuticals is tanking.
(Image credit: Gary Waters/Ikon Images/Corbis)

Does the fall of Valeant Pharmaceuticals mean the universe is a just place after all?

"Pharma bro" Martin Shkreli may have become infamous for buying up established drugs and then hiking their prices through the roof. But it was Valeant Pharmaceuticals that really pioneered the business model. Of the 19 drugs whose prices rose the fastest in 2015, half belonged to them.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Jeff Spross

Jeff Spross was the economics and business correspondent at TheWeek.com. He was previously a reporter at ThinkProgress.